MEREO BIOPHARMA GROUP PLC's ticker is MREO and the CUSIP is 589492107.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,229 | -5.1% | 1,727,570 | -2.9% | 0.00% | +33.3% |
| Q2 2023 | $2,348 | +262.9% | 1,778,772 | +94.2% | 0.00% | +200.0% |
| Q1 2023 | $647 | -31.4% | 915,909 | -27.2% | 0.00% | 0.0% |
| Q4 2022 | $943 | -99.9% | 1,257,369 | +1.9% | 0.00% | -50.0% |
| Q3 2022 | $1,062,000 | +55.7% | 1,233,614 | +102.6% | 0.00% | +100.0% |
| Q2 2022 | $682,000 | +114.5% | 608,909 | +114.6% | 0.00% | – |
| Q1 2022 | $318,000 | -9.9% | 283,800 | +28.6% | 0.00% | – |
| Q4 2021 | $353,000 | -63.4% | 220,600 | -44.7% | 0.00% | -100.0% |
| Q3 2021 | $965,000 | +6.7% | 398,900 | +39.9% | 0.00% | 0.0% |
| Q2 2021 | $904,000 | +0.4% | 285,100 | +6.7% | 0.00% | 0.0% |
| Q1 2021 | $900,000 | -30.0% | 267,200 | -25.6% | 0.00% | 0.0% |
| Q4 2020 | $1,286,000 | +2196.4% | 359,200 | +1594.3% | 0.00% | – |
| Q3 2020 | $56,000 | -63.6% | 21,200 | -57.9% | 0.00% | – |
| Q2 2020 | $154,000 | -62.8% | 50,400 | -60.1% | 0.00% | – |
| Q4 2019 | $414,000 | -16.4% | 126,323 | -24.0% | 0.00% | – |
| Q3 2019 | $495,000 | +0.2% | 166,123 | -15.2% | 0.00% | – |
| Q2 2019 | $494,000 | – | 195,923 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tejara Capital Ltd | 2,188,606 | $1,641,455 | 0.95% |
| Monaco Asset Management SAM | 2,049,661 | $1,537,246 | 0.46% |
| Rubric Capital Management LP | 10,366,120 | $7,774,590 | 0.34% |
| Clearline Capital LP | 2,052,709 | $1,539,532 | 0.28% |
| DAFNA Capital Management LLC | 1,096,513 | $822,385 | 0.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 7,364,438 | $5,523,329 | 0.23% |
| Orbimed Advisors | 10,605,522 | $7,954,142 | 0.15% |
| Octagon Capital Advisors LP | 1,000,000 | $750,000 | 0.12% |
| Rock Springs Capital Management LP | 6,244,897 | $4,683,673 | 0.11% |
| Privium Fund Management (UK) Ltd | 177,200 | $132,900 | 0.10% |